Short Interest in Mustang Bio, Inc. (NASDAQ:MBIO) Decreases By 52.0%

Mustang Bio, Inc. (NASDAQ:MBIO) was the target of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 44,000 shares, a decrease of 52.0% from the February 28th total of 91,700 shares. Based on an average trading volume of 316,300 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.8% of the shares of the stock are sold short.

Mustang Bio Stock Down 6.3 %

Shares of NASDAQ MBIO traded down $0.09 during midday trading on Friday, hitting $1.33. The stock had a trading volume of 73,124 shares, compared to its average volume of 244,964. The stock has a 50 day simple moving average of $2.65 and a 200-day simple moving average of $8.07. The company has a market capitalization of $1.27 million, a PE ratio of -0.02 and a beta of 1.82. Mustang Bio has a 1 year low of $1.28 and a 1 year high of $65.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Mustang Bio stock. Geode Capital Management LLC grew its holdings in Mustang Bio, Inc. (NASDAQ:MBIO) by 15.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 284,437 shares of the company’s stock after buying an additional 38,951 shares during the period. Geode Capital Management LLC owned 29.63% of Mustang Bio worth $50,000 as of its most recent filing with the Securities & Exchange Commission. 9.95% of the stock is owned by institutional investors and hedge funds.

Mustang Bio Company Profile

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.